(1,1'-BIPHENYL)-3-CARBOXYLIC ACID, 2',4'-DIFLUORO-4-HYDROXY-
Hereditary Amyloidosis
Boston UniversitySmall moleculePhase 2/3Dormant
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Hereditary Amyloidosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Patisiran Alnylam Pharmaceuticals | Phase 3 | A |
Revusiran Alnylam Pharmaceuticals | Phase 3 | BB |
Aln-Ttrsc02 Alnylam Pharmaceuticals | Phase 3 | BB |
Acoramidis Eidos Therapeutics, a BridgeBio company | Phase 3 | B |
Nexiguran Ziclumeran Intellia Therapeutics | Phase 3 | B |
Aln-Ttr02 Alnylam Pharmaceuticals | Phase 2 | B |
Tolcapone Boston University | Early Phase 1 | CC |
Tegsedi | D |
Same molecule, other indications
(1,1'-BIPHENYL)-3-CARBOXYLIC ACID, 2',4'-DIFLUORO-4-HYDROXY- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →